Sacituzumab Govitecan and Toripalimab for First-Line Advanced Triple-Negative Breast Cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have advanced triple-negative breast cancer that has not been treated with chemotherapy, targeted therapy, or immunotherapy for advanced disease.
- You have at least one tumor that can be measured by scans (CT or MRI).
- You are willing to receive the study treatment: a combination of sacituzumab govitecan (a targeted chemotherapy antibody) and toripalimab (an immunotherapy drug).
- You do not have symptoms from brain metastases that need urgent treatment, and you have not had prior treatment targeting HER2, Trop-2, PD-1/PD-L1, or similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—an antibody-drug conjugate that targets a protein on cancer cells and an immunotherapy that helps your immune system attack the tumor—for people with advanced triple-negative breast cancer that has already been treated. It aims to see if this combo can shrink tumors or slow the disease.
This trial tests a combination of two drugs, Sacituzumab Govitecan and Bevacizumab, for people with advanced triple-negative breast cancer that has already been treated. The goal is to see if the combination works better than standard treatments.
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
This trial tests a combination of two targeted drugs—sacituzumab tirumotecan and anlotinib—for people with triple-negative breast cancer that has spread or cannot be removed by surgery and has already been treated with at least one prior therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
This trial tests a combination of two drugs—sacituzumab govitecan and toripalimab—against another combination (toripalimab plus nab-paclitaxel) for people with advanced triple-negative breast cancer that is PD-L1 positive. The goal is to see which combination works better and has fewer side effects.
This trial tests a new combination of two drugs (Sac-TMT and Toripalimab) as the first treatment for women with advanced triple-negative breast cancer that is PD-L1 positive. The goal is to see if this combination can shrink or control the cancer better than standard treatments.
Hear when a new TNBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.